I love the idea but it would never happen. No way the FDA would ever allow a human element into a clinical review, known for being unfeeling and filled with Adcom members who put their own careers ahead of patients needs.
And by "share information" you mean tout an off topic stock while not paying attention enough to what you post - about how there is little difference between Etep and Dris according to your Doctor wife - when statistically 2 drugs could hardly be more different in terms of efficacy and safety?
Even the haters/shorts concede that Etep has far greater efficacy and a much better safety profile than Dris. They attack in other ways.
Did they get word on something that nobody else did?
It is more than just timing, and no bad news, somehow someone on the inside of the FDA mentioned something. Piper is too careful to say something unless they know for sure.
He isn't honest and he isn't a newbie, he is here hocking Summit. He is trying to trick people into buying his stock to make it go up.
You missed the point. It was a back-handed compliment to her. I will spell it out for you.
She married YOU.
You got to marry HER.
She got the better deal.
Your posting confirms it, she definitely is smarter than you.
Marrying you must have only been temporary insanity on her part.
Because stocks go down all the time.
Because they may be offsetting a large call option position so they make money either way.
Because they could be counter balancing another position like BMRN if one wins the other loses. So short both and one will be right.
Because market events like Greece and China happen all the time.
Because the FDA is unpredictable and anything can happen, even in the best of situations.
Why do people buy lottery tickets. Sure they don't win often but when they do, it's big.
See. You gave up to early. You gave back yesterday's gains, while the rest of us kept the gains and put in $0.16/share more.
I also didn't see BMRN at $5 anytime recently. Was that an intraday flash crash type? It doesn't really matter. BMRN is a great company that has come a long way. SRPT is the same way just earlier in the cycle.
The FDA is following a process. One that has no incentive to do better or faster, such is the nature of a bureaucratic government. Each and every day our country becomes more of a socialist/communist country where there is no incentive to do better. The FDA is a great example of that.
We could hear about the formal acceptance of the NDA by the FDA as early as next week, though more realistically it will be in the August 28-31 time frame. Still, could happen any day now, and shorts are not going to want to get caught on the wrong side of that one.
Wouldn't it be much higher than $264? Maybe I don't understand Yee's calculations, but was the $11B the value of the drug in terms of annual revenues or in terms of market cap to BMRN? Revenues don't seem to come close to $11B unless he is including derivative drugs that Drisapersen will lead to. So maybe it was just market cap value to BMRN, in which case it is likely higher for SRPT, as Gary pointed out, because it will establish SRPT as a leader in this part of the Biospace which will help them in future discoveries, etc.
I followed your link but all I saw was a list of disorders and I'm not smart enough to know which ones would benefit from exon skipping and I didn't see any patient counts on that page, so I guess I'm missing your point.
I agree with you completely that Sarepta on the forefront of exon skipping would be a very strong leadership position that will pay direct and indirect benefits. Direct from the current pipeline, and indirect as the current pipeline will lead to ancillary findings and make later drug compounds faster/easier to discover, target, test, and get approved.
Anyway, I was just curious what that link was supposed to show because I didn't see any quantifiable metrics.
The Advisory board is good no matter how we look at it. For advice on the NDA, for moving forward after approval to broaden the offering.
Most of all, it could be instrumental in lining up for a buyout, determining fair value, evaluating potentially multiple offers, looking for the best strategic fit, etc.